ArticleJournal of immunology (Baltimore, Md. : 1950)2025
Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development.
Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Absent in Melanoma 2 (AIM2) on Antigen-Specific CD4+ T cell Activation and Homeostasis.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) constitutes 90% of head and neck cancers. HNSCC development is linked to chronic inflammation, while established HNSCC tumors are often immune suppressive. However, both occur through mechanisms that are not fully understood. The cytosolic double-stranded DNA sensor absent in melanoma 2 (AIM2) is an inflammasome-forming protein that also has inflammasome-distinct roles in restricting tumorigenesis by limited PI3K signaling. Here, we used an experimental mouse model of HNSCC, involving treatment of wild-type (WT) and Aim2-/- mice with the carcinogen 4NQO in drinking water. Compared with WT mice, 4NQO-treated Aim2-/- mice exhibited larger tumors and increased tissue dysplasia. 4NQO-treated WT and Aim2-/- mice displayed similar tongue Il6, Tnf, Il1b, Il12, and Il10 expression and no consistent differences in PI3K or inflammasome activation, suggesting AIM2 may not regulate these factors during HNSCC. Instead, Ifng and Irf1 was elevated in 4NQO-treated Aim2-/- mice, suggesting that AIM2 restricts IFN-γ. In line with this, RNA sequencing of total tongue RNA from 4NQO-treated mice revealed that Aim2-/- mice had enhanced expression of genes related to the major histocompatibility complex protein complex, cell killing, and T cell activation compared with WT mice. We also observed increased macrophage infiltration into the tongue epithelium of 4NQO-treated Aim2-/- mice and an increased M1:M2 macrophage ratio. Using Aim2-/-/Rag1-/- double-deficient animals, we found that the adaptive immune compartment was necessary for the enhanced tumorigenesis during AIM2 deficiency. These findings suggest that AIM2 limits the progression of oral tumor development partially through regulating IFN-γ and adaptive immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.